Dr. Dinesh Patel is considered by many to be the father of biotechnology and pharmaceuticals in the Mountain West region.
Dr. Patel is a founding managing director of vSpring Capital. From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. He currently holds 15 US Patents and Foreign Counterparts. Prior to vSpring, Dr. Patel was an active angel investor in over 20 biotech and technology companies. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., a biotechnology company focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. From 1985 – 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold for $350 million to Watson Pharmaceuticals.
Born and raised in Zambia, Africa, Dr. Patel received his bachelor's degree in Pharmacy at GujaratUniversity located in Ahmedabad, Gujarat, India his master's degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan. Dr. Patel led the firm's investments in Altea Therapeutics, Axial, Coherex, Exagen, Inflabloc, Numira, Lineagen, Protolex, Q Therapeutics, ZARS and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.